ALKS 2680 not checked

Alkermes, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
5 active
7 in total · 7 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive ALKS 2680 tablets, orally, daily, for 12 weeks”In the company’s words, NCT07455383 on ClinicalTrials.gov
Tested for
Narcolepsy Type 1 (3 trials), Narcolepsy Type 2 (2 trials), Idiopathic Hypersomnia (2 trials)
Main trialPhase 3
“The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.”In the company’s words, NCT07455383 on ClinicalTrials.gov
Other names
Alixorexton

Other drugs for Narcolepsy Type 1

All 9 drugs for Narcolepsy Type 1

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Recruiting May 2027 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Phase 3Recruiting May 2027 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Phase 3Recruiting Jun 2027 A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
Phase 2/3Recruiting Jun 2030 A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Phase 2Active, not recruiting Nov 2026 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Phase 2Completed 19 Jun 2025 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Phase 2Completed 11 Nov 2025 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ALKS 2680

Following is part of Solo: you see every change to ALKS 2680 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in